Revenio Group Oyj REVXF
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective and easy-to-use health tech-related screening devices for the detection of diseases of significance to public health. The company is focused on the detection and measurement of glaucoma, skin cancer and asthma. Its products are sold all around the world. It operates in the segment of Health technology which involves the design, manufacture, and sales of tonometers; design, manufacture, and sales of bone density measurement device; and management of the group's research and development projects.